225Ac-J591,177Lu-PSMA-I
novartis,alkido
['crpc', '225ac']
 and fellow researchers carried out a phase 1/2 trial investigating the combination of 225ac-j591 with 177lu-psma-i&amp;t to determine if the treatment offered a psa decline for mcrpc. learn more: #asco23 #asco2023 
GU Oncology Now brings you the latest research and updates in #prostatecancer, #bladdercancer, #kidneycancer, and more in the genitourinary oncology sphere.